Home > Cardiology > ESC 2022 > Rheumatic heart disease-associated AF: standard-of-care holds ground

Rheumatic heart disease-associated AF: standard-of-care holds ground

Presented By
Prof. Ganesan Karthikeyan, All India Institute of Medical Sciences, New Delhi, India
Conference
ESC 2022
Trial
Phase 3, INVICTUS
In patients with rheumatic heart disease-associated atrial fibrillation (AF), vitamin K antagonist therapy was non-inferior to rivaroxaban for the rate of a composite of cardiovascular events or death, without a higher risk of bleeding. Prof. Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) presented the findings of the INVICTUS (NCT02832544) trial, which compared cardiovascular outcomes in patients with rheumatic heart disease-associated AF randomised to either receive treatment with factor Xa inhibitor rivaroxaban or with a standard vitamin K antagonist. The primary efficacy endpoint was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or non-cardiac) or unknown causes. The primary safety endpoint was major bleeding according to the ISTH. Of the 4,531 patients included in the fi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on